Please use this identifier to cite or link to this item:
|Title:||The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations.||Austin Authors:||Vella, Laura J;Andrews, Miles C;Pasam, Anupama;Woods, Katherine;Behren, Andreas;Cebon, Jonathan S||Affiliation:||Ludwig Institute for Cancer Research; Melbourne-Austin Branch; Cancer Immuno-biology Laboratory ; Heidelberg, Australia||Issue Date:||3-Jul-2014||Publication information:||Oncoimmunology 2014; 3(7): e946367||Abstract:||Metastatic melanoma is frequently fatal. Optimal treatment regimens require both rapid and durable disease control, likely best achieved by combining targeted agents with immunotherapeutics. In order to accomplish this, a detailed understanding of the immune consequences of the kinase inhibitors used to treat melanoma is required.||Gov't Doc #:||25610732||URI:||http://ahro.austin.org.au/austinjspui/handle/1/12590||DOI:||10.4161/21624011.2014.946367||URL:||https://pubmed.ncbi.nlm.nih.gov/25610732||Type:||Journal Article||Subjects:||BRAF
|Appears in Collections:||Journal articles|
Show full item record
checked on Nov 29, 2022
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.